Prophylactic and early outpatient treatment of COVID-19 in patients with kidney disease: considerations from the Immunonephrology Working Group of the European Renal Association (ERA-IWG)

Basit Öğe Kaydı
dc.contributor.authorHilhorst, Marc
dc.contributor.authorBemelman, Frederike J.
dc.contributor.authorBruchfeld, Annette
dc.contributor.authorFernandez-Juarez, Gema M.
dc.contributor.authorFloege, Juergen
dc.contributor.authorFrangou, Eleni
dc.contributor.authorGoumenos, Dimitrios
dc.date.accessioned2024-02-23T14:21:02Z
dc.date.available2024-02-23T14:21:02Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic led to rapid vaccine development and large global vaccination schemes. However, patients with immune-mediated kidney disease, chronic kidney diseases and kidney transplant recipients show high non-response rates to vaccination despite more than three vaccinations and, consequently, reduced viral clearance capacity when infected while receiving certain immunosuppressants, carrying an elevated risk for coronavirus disease 2019 (COVID-19)-related morbidity and mortality. SARS-CoV-2 evolution has been characterized by the emergence of novel variants and spike mutations contributing to waning efficacy of neutralizing antibodies. To this end, the therapeutic field expands from vaccination towards a combined approach of immunization, pre-exposure prophylaxis and early post-exposure treatment using direct-acting antivirals and neutralizing monoclonal antibodies to treat early in the disease course and avoid hospitalization. This expert opinion paper from the Immunonephrology Working Group of the European Renal Association (ERA-IWG) summarizes available prophylactic and/or early treatment options (i.e. neutralizing monoclonal antibodies and direct-acting antivirals) of SARS-CoV-2-infected patients with immune-mediated kidney disease, chronic kidney disease and kidney transplant recipients.en_US
dc.identifier.doi10.1093/ndt/gfad044
dc.identifier.endpage1816en_US
dc.identifier.issn0931-0509
dc.identifier.issn1460-2385
dc.identifier.issue8en_US
dc.identifier.pmid36881727en_US
dc.identifier.scopus2-s2.0-85164575081en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1807en_US
dc.identifier.urihttps://doi.org/10.1093/ndt/gfad044
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13420
dc.identifier.volume38en_US
dc.identifier.wosWOS:001006211300001en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofNephrology Dialysis Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntiviral Therapyen_US
dc.subjectCovid-19en_US
dc.subjectKidneyen_US
dc.subjectProphylaxisen_US
dc.subjectTransplantationen_US
dc.titleProphylactic and early outpatient treatment of COVID-19 in patients with kidney disease: considerations from the Immunonephrology Working Group of the European Renal Association (ERA-IWG)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu